Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 14Observational 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1SCLC, Extensive Stage 1Melanoma 1Lung Neoplasms 1Liver Diseases 1Esophageal Neoplasms 1Breast Neoplasms 1Advanced Colorectal Carcinoma 1

Interventions

Blood Specimen Collection 14Nivolumab 13Ipilimumab 12pembrolizumab 11trametinib 9Surveys and Questionnaires 9Gene Expression Profiling 9dabrafenib 8Biopsy 6Specimen Handling 5Immunotherapy 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 4encorafenib 3binimetinib 3atezolizumab 3Restraint, Physical 3Quality of Life 3Polymerase Chain Reaction 3Introns 3Flow Cytometry 3Drug Therapy 3Data Collection 3tremelimumab 2pimonidazole 2cobimetinib 2aldesleukin 2Watchful Waiting 2Vemurafenib 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Melanoma × toripalimab × Clear all
NCT04234620 2020-01-21

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Shanghai Junshi Bioscience Co., Ltd.

Unknown
800 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡